HRP20161233T1 - Neurozaštita u demijelinizirajućim bolestima - Google Patents
Neurozaštita u demijelinizirajućim bolestima Download PDFInfo
- Publication number
- HRP20161233T1 HRP20161233T1 HRP20161233TT HRP20161233T HRP20161233T1 HR P20161233 T1 HRP20161233 T1 HR P20161233T1 HR P20161233T T HRP20161233T T HR P20161233TT HR P20161233 T HRP20161233 T HR P20161233T HR P20161233 T1 HRP20161233 T1 HR P20161233T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- use according
- subject
- therapeutically effective
- Prior art date
Links
- 208000016192 Demyelinating disease Diseases 0.000 title 1
- 230000004112 neuroprotection Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 23
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 5
- 229960004419 dimethyl fumarate Drugs 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 4
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims 3
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims 3
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims 3
- 229940005650 monomethyl fumarate Drugs 0.000 claims 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- -1 microtablets Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (23)
1. Barem jedan spoj odabran između dimetil fumarata i monometil fumarata, ili njihove farmaceutski prikladne soli, za uporabu u liječenju progresivnog oblika multiple skleroze u subjekta.
2. Spoj ili sol za uporabu prema zahtjevu 1, gdje subjekt pokazuje progresiju na EDSS ljestvici (engl. Enhanced Disability Status Scale) barem za jedan bod u vremenu od jedne godine prije primjene spoja.
3. Spoj ili sol za uporabu prema zahtjevu 1, gdje subjekt pokazuje barem 25% porasta T1 lezija u vremenu od jedne godine prije primjene spoja.
4. Spoj ili sol za uporabu prema zahtjevu 1, gdje subjekt ima EDSS rezultat od barem 3.
5. Spoj ili sol za uporabu prema zahtjevu 1, gdje subjekt ima više od 10 hipointenzivnih T1 lezija.
6. Spoj ili sol za uporabu prema zahtjevu 1, gdje subjekt ima primarnu progresivnu multiplu sklerozu.
7. Spoj ili sol za uporabu prema zahtjevu 1, gdje subjekt ima sekundarnu progresivnu multiplu sklerozu.
8. Spoj ili sol za uporabu prema zahtjevu 7, gdje subjekt ima EDSS rezultat veći od 5.
9. Barem jedan spoj odabran između dimetil fumarata i monometil fumarata, ili njihove farmaceutski prikladne soli, za uporabu u liječenju Devicove bolesti u subjekta.
10. Spoj ili sol za uporabu prema bilo kojem od zahtjeva 1 do 9, gdje se spoj primjenjuje oralno u terapijski učinkovitoj dozi.
11. Spoj ili sol za uporabu prema zahtjevu 10, gdje je terapijski učinkovita doza od oko 200 mg do oko 800 mg dnevno.
12. Spoj ili sol za uporabu prema zahtjevu 11, gdje je terapijski učinkovita doza od oko 480 mg do oko 720 mg dnevno.
13. Spoj ili sol za uporabu prema zahtjevu 12, gdje je terapijski učinkovita doza oko 480 mg.
14. Spoj ili sol za uporabu prema zahtjevu 12, gdje je terapijski učinkovita doza oko 720 mg.
15. Spoj ili sol za uporabu prema bilo kojem od zahtjeva 10 do 14, gdje se terapijski učinkovita doza daje u odvojenim primjenama od 2, 3, 4 ili 6 jednakih doza.
16. Spoj ili sol za uporabu prema zahtjevu 15, gdje se doza daje u odvojenim primjenama od 2 jednake doze.
17. Spoj ili sol za uporabu prema zahtjevu 15, gdje se doza daje u odvojenim primjenama od 3 jednake doze.
18. Spoj ili sol za uporabu prema bilo kojem od zahtjeva 1 do 17, gdje je spoj dimetil fumarat.
19. Spoj ili sol za uporabu prema bilo kojem od zahtjeva 1 do 17, gdje je spoj monometil fumarat.
20. Spoj ili sol za uporabu prema bilo kojem od zahtjeva 1 do 19, gdje je spoj u obliku pilula, tableta, mikrotableta, peleta, mikropeleta, kapsula, kapsula koje sadrže mikrotablete ili tekućih oblika za oralnu primjenu.
21. Spoj ili sol za uporabu prema bilo kojem od zahtjeva 1 do 19, gdje uporaba obuhvaća oralnu primjenu jedne ili više kapsula koje sadrže farmaceutski pripravak koji se sastoji u biti od 60 do 240 mg dimetil fumarata.
22. Spoj ili sol za uporabu prema zahtjevu 21, gdje uporaba obuhvaća oralnu primjenu jedne ili više kapsula koje sadrže farmaceutski pripravak koji se sastoji u biti od 120 mg dimetil fumarata.
23. Spoj ili sol za uporabu prema bilo kojem od zahtjeva 1 do 22, gdje se spoj primjenjuje u obliku s produljenim ili kontroliranim oslobađanjem.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88892507P | 2007-02-08 | 2007-02-08 | |
EP08737369.2A EP2139467B1 (en) | 2007-02-08 | 2008-02-07 | Neuroprotection in demyelinating diseases |
PCT/IB2008/000779 WO2008096271A2 (en) | 2007-02-08 | 2008-02-07 | Neuroprotection in demyelinating diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161233T1 true HRP20161233T1 (hr) | 2016-12-02 |
Family
ID=39682167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161233TT HRP20161233T1 (hr) | 2007-02-08 | 2016-09-27 | Neurozaštita u demijelinizirajućim bolestima |
Country Status (13)
Country | Link |
---|---|
US (4) | US20100130607A1 (hr) |
EP (2) | EP3135282A1 (hr) |
DK (1) | DK2139467T3 (hr) |
ES (1) | ES2599227T3 (hr) |
HK (1) | HK1140413A1 (hr) |
HR (1) | HRP20161233T1 (hr) |
HU (1) | HUE032251T2 (hr) |
LT (1) | LT2139467T (hr) |
PL (1) | PL2139467T3 (hr) |
PT (1) | PT2139467T (hr) |
RS (1) | RS55215B1 (hr) |
SI (1) | SI2139467T1 (hr) |
WO (1) | WO2008096271A2 (hr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
AU2004269903B2 (en) * | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
US20140099364A2 (en) | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US20100130607A1 (en) | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
ES2916649T3 (es) | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Composiciones y usos para el tratamiento de la esclerosis múltiple |
EP2650279A3 (en) | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
PT2379063E (pt) | 2009-01-09 | 2013-05-03 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
EP2533634B1 (en) | 2010-02-12 | 2015-10-21 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
US20140163100A1 (en) * | 2011-05-26 | 2014-06-12 | Biogen Idec Ma Inc. | Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content |
CN103649041A (zh) | 2011-06-08 | 2014-03-19 | 比奥根艾迪克Ma公司 | 制备高纯度和结晶的富马酸二甲酯的方法 |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
WO2014031844A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
UA119032C2 (uk) * | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
JP6506174B2 (ja) | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
RS57497B1 (sr) | 2013-03-14 | 2018-10-31 | Alkermes Pharma Ireland Ltd | Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | (n,n-二乙基胺甲醯基)甲基(2e)丁-2-烯-1,4-二酸甲酯之晶形、合成方法及用途 |
CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
EP3110793B1 (en) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
EP3501510B1 (en) | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
MA40985A (fr) * | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
MA41785A (fr) * | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
AU2016379345B2 (en) | 2015-12-22 | 2020-09-17 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
SG11201804811WA (en) | 2015-12-22 | 2018-07-30 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
JP2019526544A (ja) | 2016-08-24 | 2019-09-19 | ゾゲニクス インターナショナル リミテッド | 5−ht2bアゴニストの形成を阻害するための製剤およびその使用方法 |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
EP3737471A1 (en) | 2018-01-11 | 2020-11-18 | M Et P Pharma AG | Treatment of demyelinating diseases |
WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
US20230078820A1 (en) * | 2021-09-01 | 2023-03-16 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3127432A1 (de) * | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
US5149695A (en) * | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
JPS61194020A (ja) * | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
US5214196A (en) * | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
US5424332A (en) * | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
US5484610A (en) * | 1991-01-02 | 1996-01-16 | Macromed, Inc. | pH and temperature sensitive terpolymers for oral drug delivery |
AU1271592A (en) * | 1991-01-18 | 1992-08-27 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
IT1251166B (it) * | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
FR2694693B1 (fr) * | 1992-07-28 | 1994-10-28 | Abrax Bio Labs Sa | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
US5407772A (en) * | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
US5972363A (en) * | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
JP2001521002A (ja) * | 1997-10-24 | 2001-11-06 | コーネル リサーチ ファンデーション インク. | 脳の代謝機能不全のための栄養補充剤 |
US20050245612A1 (en) * | 2004-05-03 | 2005-11-03 | Blass John P | Pharmaceutical compositions for metabolic insufficiencies |
DE19814358C2 (de) * | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
DE19848260C2 (de) * | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
US6537584B1 (en) * | 1999-11-12 | 2003-03-25 | Macromed, Inc. | Polymer blends that swell in an acidic environment and deswell in a basic environment |
DE10000577A1 (de) * | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
ES2292564T3 (es) * | 2000-02-11 | 2008-03-16 | Philadelphia Health And Education Corporation | Diferenciacion de celulas de la medula osea en celulas neuronales y usos asociados. |
WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
WO2002055063A2 (de) * | 2001-01-12 | 2002-07-18 | Fumapharm Ag | Fumarsäureamide |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
TR200202175T1 (tr) * | 2001-02-14 | 2003-10-21 | Rath Matthias | Hücrelerin biyoenerji metabolizmasında bulunan biyokimyasal bileşiklerin kompozisyonları |
US20030104997A1 (en) * | 2001-09-05 | 2003-06-05 | Black Ira B. | Multi-lineage directed induction of bone marrow stromal cell differentiation |
DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
US6830759B2 (en) * | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
AU2004269903B2 (en) * | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
WO2005097082A1 (en) * | 2004-03-31 | 2005-10-20 | Bpsi Holdings, Inc. | Enteric coatings for orally ingestible substrates |
US20140099364A2 (en) | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US7638119B2 (en) * | 2004-12-02 | 2009-12-29 | Wisconsin Alumni Research Foundation | Method of diminishing the symptoms of neurodegenerative disease |
EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
DE102005022845A1 (de) * | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
US20080089861A1 (en) * | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
ES2916649T3 (es) * | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Composiciones y usos para el tratamiento de la esclerosis múltiple |
US20100130607A1 (en) | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
US20080274182A1 (en) * | 2007-05-03 | 2008-11-06 | Regina Helena Alida Boekema | Tablet coatings made from modified carboxymethylcellulose materials |
EP2650279A3 (en) * | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
PT2379063E (pt) * | 2009-01-09 | 2013-05-03 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
EP2533634B1 (en) * | 2010-02-12 | 2015-10-21 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
CN114146080A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
-
2008
- 2008-02-07 US US12/525,805 patent/US20100130607A1/en not_active Abandoned
- 2008-02-07 EP EP16188566.0A patent/EP3135282A1/en not_active Withdrawn
- 2008-02-07 SI SI200831679A patent/SI2139467T1/sl unknown
- 2008-02-07 RS RS20160808A patent/RS55215B1/sr unknown
- 2008-02-07 HU HUE08737369A patent/HUE032251T2/en unknown
- 2008-02-07 PL PL08737369T patent/PL2139467T3/pl unknown
- 2008-02-07 ES ES08737369.2T patent/ES2599227T3/es active Active
- 2008-02-07 LT LTEP08737369.2T patent/LT2139467T/lt unknown
- 2008-02-07 WO PCT/IB2008/000779 patent/WO2008096271A2/en active Application Filing
- 2008-02-07 PT PT87373692T patent/PT2139467T/pt unknown
- 2008-02-07 EP EP08737369.2A patent/EP2139467B1/en not_active Revoked
- 2008-02-07 DK DK08737369.2T patent/DK2139467T3/da active
-
2010
- 2010-07-05 HK HK10106524.0A patent/HK1140413A1/zh not_active IP Right Cessation
-
2013
- 2013-03-14 US US13/826,354 patent/US20130302410A1/en not_active Abandoned
-
2014
- 2014-04-29 US US14/264,653 patent/US20140323570A1/en not_active Abandoned
-
2016
- 2016-09-27 HR HRP20161233TT patent/HRP20161233T1/hr unknown
-
2018
- 2018-05-25 US US15/989,683 patent/US20180271821A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2139467A2 (en) | 2010-01-06 |
EP2139467B1 (en) | 2016-09-21 |
WO2008096271A3 (en) | 2008-11-27 |
HK1140413A1 (zh) | 2010-10-15 |
DK2139467T3 (da) | 2017-01-02 |
SI2139467T1 (sl) | 2017-01-31 |
HUE032251T2 (en) | 2017-09-28 |
US20130302410A1 (en) | 2013-11-14 |
PT2139467T (pt) | 2016-12-16 |
WO2008096271A2 (en) | 2008-08-14 |
US20180271821A1 (en) | 2018-09-27 |
LT2139467T (lt) | 2016-10-10 |
PL2139467T3 (pl) | 2017-08-31 |
US20100130607A1 (en) | 2010-05-27 |
EP3135282A1 (en) | 2017-03-01 |
ES2599227T3 (es) | 2017-01-31 |
RS55215B1 (sr) | 2017-02-28 |
US20140323570A1 (en) | 2014-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161233T1 (hr) | Neurozaštita u demijelinizirajućim bolestima | |
JP2005515966A5 (hr) | ||
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
JP2005515964A5 (hr) | ||
JP2006506378A5 (hr) | ||
HRP20151350T1 (hr) | Neuroprotekcija kod demijelinizacijskih bolesti | |
HRP20130057T1 (hr) | Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom | |
CO4750822A1 (es) | Formulaciones farmaceuticas tada para la administracion en el tracto gastrointestinal y procesos para elaborar las mismas | |
JP2008533127A5 (hr) | ||
JP2003526595A5 (hr) | ||
WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
HRP20220332T1 (hr) | Farmaceutski pripravak koji sadrži drospirenon za uporabu kao kontraceptiv | |
SI2501234T1 (en) | METHODS AND INGREDIENTS FOR TREATMENT OF SYMPTOMS RELATED TO POST-TRAUMATIC STRESS EMISSIONS WITH THE USE OF CYCLOBENZAPRINE | |
JP2008533022A5 (hr) | ||
JP2011500781A5 (hr) | ||
JP2004505036A5 (hr) | ||
HRP20161717T1 (hr) | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama | |
JP2007534731A5 (hr) | ||
KR102055859B1 (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
JP2007023026A (ja) | イブプロフェン含有経口用医薬組成物 | |
JP2013500943A5 (hr) | ||
JP4614640B2 (ja) | 解熱剤組成物 | |
EP2034829A1 (en) | Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association | |
JP4384435B2 (ja) | くしゃみ抑制組成物 | |
JP4614638B2 (ja) | 鎮痛剤組成物 |